openPR Logo
Press release

Lysosomal Acid Lipase (LAL) Deficiency Treatment Market : Growth, Demand and Key Players to 2024

08-04-2017 04:39 PM CET | Health & Medicine

Press release from: Transparency Market Research

Lysosomal Acid Lipase (LAL) Deficiency Treatment Market :

The December 2015 U.S. FDA approval of a breakthrough drug in the LAL deficiency treatment market, has set the ball rolling for tremendous potential in the growth of this rare-disease market. Lysosomal Acid Lipase (LAL) Deficiency, also known as Cholesterol Ester Storage Disorder (CESD), Wolman’s Disease or LAL deficiency, is an inherited, ultra-rare genetic disease affecting children as well as adults. Lysosomal acid lipase (LAL) is responsible for the hydrolysis of cholesterol esters and triglycerides. Patients with LAL deficiency have no or little LAL enzyme activity which results in the accumulation of fats within various body cells that leads to high cholesterol and triglycerides, and a very low HDL-cholesterol level. There are two main types of LAL disorder: early onset Wolman Disease and late onset CESD. Wolman disease is very rare, with an incidence of less than one in 100,000 live births. CESD is a less severe, later-onset disorder which can occur in adults at any stage in life, having an incidence of about one in 25 per million births. While Wolman disease is a relatively occurrence, the infants affected with it usually die within the first year of birth after experiencing growth failure, liver fibrosis, and cirrhosis. In late onset LAL deficiency, the accumulation of cholesteryl esters and triglycerides in blood vessels, vital organs, and other tissues of adults, results in progressive and multiple-organ damage which includes fibrosis, cirrhosis, liver failure, accelerated atherosclerosis, and cardiovascular disease.

View Report @ http://www.transparencymarketresearch.com/lysosomal-acid-lipase-deficiency-treatment-market.html

Since LAL disease has symptoms similar to many other diseases, for instance, heart disease, it is often misdiagnosed. The disease in its late onset form does not affect everyone equally and thus symptoms can vary from person to person, often manifesting as mild symptoms which consequently also makes the disease underdiagnosed worldwide. The biggest factor that shall drive the market is that currently, apart from a recently approved drug by U.S. FDA known as Kanuma (sebelipase alfa), there is no approved treatment available for the disease. Thus, tremendous business opportunity lies in the investment of finding therapies for treatment in this market. Lack of awareness regarding disease diagnosis and untimely treatment due to ignorance of symptoms may restrain the growth of the market.

The global market for lysosomal acid lipase (LAL) deficiency is segmented on basis of type of therapy, type of drug, disease indication and geography:

Segmentation by Type of Therapy (no. of surgeries)
Liver Transplant
Hematopoietic Stem Cell Transplant
Segmentation by Type of Drug
Statins and other dyslipidemia drugs
Sebelipase alfa (Kanuma)
Segmentation by Disease Indication
Wolman Disease
Cholesteryl ester storage disease (CESD)
LAL deficiency is a chronic progressive genetic metabolic disease associated with substantial morbidity as well as premature mortality. It is an ultra-rare disease, which is defined as a disease that affects fewer than 20 patients per one million of the general population. The current management practice for the disease involves taking lipid lowering medications such as statins, to overcome symptoms of lipid accumulation. However, progression of the disease often necessitates the patient to undergo a liver transplant. The market for lysosomal acid lipase (LAL) deficiency is segmented based on number of surgeries: for liver transplant and for hematopoietic stem cell transplant.  A liver transplant may give LAL patients respite from liver failure, but it does not tackle the underlying cause of the disease and may not stop disease progression in extra-hepatic organs, which include the heart and kidneys. However, it is still an option for patients who wish to increase chances of survival. Although hematopoietic stem cell transplant has been performed in a few infants with lysosomal acid lipase (LAL) deficiency, it has been associated with complications and the long term outcomes are unknown. Thus, the liver transplant segment shall witness more number of surgeries during the forecast period compared to the hematopoietic stem cell transplant segment. 

Get accurate market forecast and analysis on the Lysosomal Acid Lipase (LAL) Deficiency Treatment Market. Request a sample to stay abreast on the key trends impacting this market.

http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=15329

Based on disease indication, sebalipase alfa segment is expected to contribute largest share in global lysosomal acid lipase (LAL) deficiency treatment market due to it being the only approved mainstay treatment for the disease. Statins although helpful in symptom management for lysosomal acid lipase (LAL) deficiency, are not effective in completely preventing the progression of the disease, resulting in their estimated lower share in the market compared to sebalipase alfa. Moreover, the value garnering segment would be sebalipase alfa due to its higher cost of treatment and also being the preferred treatment due to it being the only approved drug for this indication. On the basis of disease indication, the market has been segmented into wolman disease and cholesteryl ester storage disease (CESD). The market for CESD is anticipated to be higher due to comparatively higher need in this segment.

On the basis of regional presence, global lysosomal acid lipase (LAL) deficiency treatment market is segmented into five key regions viz.  North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America and Europe are expected to lead the global lysosomal acid lipase (LAL) deficiency treatment market due to high prevalence of this rare disease.

Some of the major players in global lysosomal acid lipase (LAL) deficiency treatment market are Alexion Pharmaceutical Inc., AstraZeneca plc., Merck & Co., Inc., Pfizer, Inc. and Teva Pharmaceutical Industries Ltd.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

US Office Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lysosomal Acid Lipase (LAL) Deficiency Treatment Market : Growth, Demand and Key Players to 2024 here

News-ID: 656791 • Views: 318

More Releases from Transparency Market Research

Effervescent Packaging Market: Rising Demand for Fast Dissolving Drug Delivery S …
A recent study by Transparency Market Research (TMR) has detected that the global effervescent packaging market is heavily dependent on product innovation and in the near future, a number of strategic mergers and acquisitions will follow that will define the leader. Some of the key companies currently operating in the global effervescent packaging market are Sanner GmbH, Oracle Packaging, Inc., Unither Pharmaceuticals, Romaco Pharmatechnik GmbH, Parekhplast India Ltd., Tower Laboratories
Form-fill-seal Machines Market: Prosperity of Packaged Food and Beverage Industr …
An up-to-date study by Transparency Market Research (TMR) reveals that the global form-fill-seal machines market is fragmented in nature, although Robert Bosch GmbH does hold a position of strength, accounting for 11% of the overall market shares in 2017. Some of the other key players identified by the report who are making a mark in the global form-fill-seal machines market are: Tokyo Automatic Machinery Works Ltd., Uflex Ltd., Hayssen Flexible
Chatbot Market: Key Players and Production Information analysis
A 27.8% CAGR (Compound Annual Growth Rate) is set to mark the forecast period between 2016 and 2024, as per a Transparency Market Research (TMR) report. And, as per the analysts at TMR , some of the factors that the growth shall be attributed to are increasing popularity and adoption of Artificial Intelligence (AI) across industry verticals, including end-users, and innovation marking the landscape in a big way. This will
Digital Voice Recorder Market: Rising Allocations OnanalysisAnd Innovation
With the presence of a copious number of companies, the global market for digital voice recorder is fragmented with intense competition. In this scenario, top companies are aggressively engaged in technological advancements to serve ever-changing consumer demand, for which they are investing heavily in this market. In the years ahead, these players are likely to concentrate on regional expansion, for which they might resort to business alliances with regional players. Key

All 5 Releases


More Releases for LAL

Talk on Corrosion & Electrochemistry at Banasthali by Dr S Lal Plating Consultan …
According to NASA, the cost of corrosion to the USA is around $276 billion per year and this very statement itself is enough to drive the importance of this field of study. Dr Sudarshan Lal Sharma is presently a Plating consultatnt at Mechanicsburg, Pennsylvania – PA USA. He holds a Masters with a first rank in Physical Chemistry from Vikram University Ujjain, PhD in Electro Analytical Chemistry from Agra University and
Ram Lal Ram Chandra India Ltd excited to launch its new Brand ShiBui BAGS Backpa …
Shibui bags exclusively enter into the marketplace of Amazon. The idea of the Shibuibags is to offer a product that reflects the values of customer comfort, style, colour and individuality. Shibui will provide the best quality of backpacks, laptops bags, sling bags, wallets and travel bags. Our bags are exclusive and modernized. Our major focus will be on giving lifestyles backpacks which are designed to be elegant and make a style. The
Global Laser-assisted Liposuction (LAL) Equipment Market 2018 - Syneron, Cutera, …
Apex Market Reports, recently published a detailed market research study focused on the “Laser-assisted Liposuction (LAL) Equipment Market” across the global, regional and country level. The report provides 360° analysis of “Laser-assisted Liposuction (LAL) Equipment Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend
Lysosomal Acid Lipase (LAL) Deficiency Treatment Market: Business Intelligence & …
The December 2015 U.S. FDA approval of a breakthrough drug in the LAL deficiency treatment market, has set the ball rolling for tremendous potential in the growth of this rare-disease market. Lysosomal Acid Lipase (LAL) Deficiency, also known as Cholesterol Ester Storage Disorder (CESD), Wolman’s Disease or LAL deficiency, is an inherited, ultra-rare genetic disease affecting children as well as adults. Lysosomal acid lipase (LAL) is responsible for the hydrolysis
Lysosomal Acid Lipase (LAL) Deficiency Treatment Market Research Report: Analysi …
The December 2015 U.S. FDA approval of a breakthrough drug in the LAL deficiency treatment market, has set the ball rolling for tremendous potential in the growth of this rare-disease market. Lysosomal Acid Lipase (LAL) Deficiency, also known as Cholesterol Ester Storage Disorder (CESD), Wolman’s Disease or LAL deficiency, is an inherited, ultra-rare genetic disease affecting children as well as adults. Lysosomal acid lipase (LAL) is responsible for the hydrolysis
Lysosomal Acid Lipase (LAL) Deficiency Treatment Market Size & Forecast 2016 to …
The December 2015 U.S. FDA approval of a breakthrough drug in the LAL deficiency treatment market, has set the ball rolling for tremendous potential in the growth of this rare-disease market. Lysosomal Acid Lipase (LAL) Deficiency, also known as Cholesterol Ester Storage Disorder (CESD), Wolman’s Disease or LAL deficiency, is an inherited, ultra-rare genetic disease affecting children as well as adults. Lysosomal acid lipase (LAL) is responsible for the hydrolysis